Literature DB >> 8144581

The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide.

A M Schmidt1, R Mora, R Cao, S D Yan, J Brett, R Ramakrishnan, T C Tsang, M Simionescu, D Stern.   

Abstract

Advanced glycation end products (AGEs), formed as the result of the extended interaction of proteins with ketoses, modulate central properties of endothelial cells and mononuclear phagocytes by interacting with a cell surface binding site comprised of a novel integral membrane protein (receptor for AGE = RAGE) and a lactoferrin-like polypeptide (LF-L), the latter having sequence identity to lactoferrin (LF). To further understand this cellular binding site, the interaction of RAGE with LF-L and LF was characterized. By ligand blotting and a solid state competitive binding assay, 125I-LF-L and 125I-LF bound to RAGE immobilized on nitrocellulose membranes or polypropylene tubes in a time-dependent and reversible manner, demonstrating a high affinity component with Kd approximately 100 pM. The interaction of 125I-LF-L and 125I-LF with RAGE was independent of iron in LF and was competed by addition of an excess of unlabeled carboxyl-terminal portion of LF. Cross-linking studies with purified 125I-LF-L and RAGE, in the presence of disuccinimidyl suberate, showed a new, slowly migrating band, corresponding to a complex of RAGE and LF-L, and cross-linking on mouse aortic endothelial cells showed two new slowly migrating bands on immunoblotting visualized with both anti-RAGE IgG and anti-LF-L IgG. These data lead us to propose that the endothelial cell surface binding site for AGEs consists of LF-L bound noncovalently to RAGE anchored in the cell membrane.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144581

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

2.  Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells.

Authors:  A Gugliucci; M Bendayan
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

3.  Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins.

Authors:  S Fu; M X Fu; J W Baynes; S R Thorpe; R T Dean
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

4.  Acute hyperglycemic exacerbation of lung ischemia-reperfusion injury is mediated by receptor for advanced glycation end-products signaling.

Authors:  Damien J Lapar; Vanessa A Hajzus; Yunge Zhao; Christine L Lau; Brent A French; Irving L Kron; Ashish K Sharma; Victor E Laubach
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-06       Impact factor: 6.914

Review 5.  Understanding RAGE, the receptor for advanced glycation end products.

Authors:  Angelika Bierhaus; Per M Humpert; Michael Morcos; Thoralf Wendt; Triantafyllos Chavakis; Bernd Arnold; David M Stern; Peter P Nawroth
Journal:  J Mol Med (Berl)       Date:  2005-08-24       Impact factor: 4.599

6.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE).

Authors:  M D Oldfield; L A Bach; J M Forbes; D Nikolic-Paterson; A McRobert; V Thallas; R C Atkins; T Osicka; G Jerums; M E Cooper
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

7.  Isolated rat hepatocytes differentially bind and internalize bovine lactoferrin N- and C-lobes.

Authors:  M P Sitaram; D D McAbee
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

8.  Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE).

Authors:  Lana E Hanford; Jan J Enghild; Zuzana Valnickova; Steen V Petersen; Lisa M Schaefer; Todd M Schaefer; Todd A Reinhart; Tim D Oury
Journal:  J Biol Chem       Date:  2004-09-20       Impact factor: 5.157

Review 9.  Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.

Authors:  Susan J Zieman; David A Kass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.

Authors:  J L Wautier; M P Wautier; A M Schmidt; G M Anderson; O Hori; C Zoukourian; L Capron; O Chappey; S D Yan; J Brett
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.